Company Overview
Company Type: Public Company
Website: www.medicure.com
Number of Employees: 38
Ticker: MPH (TSXV)
Year Founded: 1997


Business Description
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
23.2
Market Capitalization
17.4
TEV/Total Revenue
0.5x
EBITDA
3.6
Total Enterprise Value
12.7
TEV/EBITDA
3.2x
EBIT
1.9
Cash & ST Invst.
5.4
P/Diluted EPS Before Extra
8.4x
Net Income
2.1
Total Debt
0.7
Price/Tang BV
2.0x
Capital Expenditure
0.0
Total Assets
29.2
Total Debt/EBITDA
0.2x
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Friesen, Albert David
Founder, CEO & Chairman of the board
Owens, Neil 
President & COO
Uddin, Haaris 
Chief Financial Officer
Saba, Reuben 
Vice President of Scientific & Medical Affairs

Key Board Members
Name
Title
Friesen, Albert David
Founder, CEO & Chairman of the board
Armstrong, Paul W.
Chairman of Scientific Advisory Board
Fawkes, Brent 
Independent Director
Naimark, Arnold 
Independent Director
Hanessian, Stephen 
Member of Scientific Advisory Board
Hassell, Trevor 
Member of Scientific Advisory Board
Karmazyn, Morris 
Member of Scientific Advisory Board
Kinley, James F.
Director
Lincoff, A. Michael
Member of Scientific Advisory Board
Quick, Peter C.
Independent Director
Theroux, Pierre 
Member of Scientific Advisory Board
Weitz, Jeffrey 
Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
2-1250 Waverley Street | Winnipeg, MB | R3T 6C6 | Canada
Phone: 204-487-7412   Fax: 204-488-9823

Current and Pending Investors
CentreStone Ventures Inc., Elliott Management Corporation, PenderFund Capital Management Ltd., Renaissance Capital Manitoba Ventures Fund LP, SciTech Management Inc.

Prior Investors
Crocus Fund, Crocus Investment Fund, Crown Capital Partners Inc. (TSX:CRWN), Genesys Venture Inc., Satellite Asset Management, L.P.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 1.67
Market Cap (mm)
17.4
Open
 1.61
Shares Out. (mm)
10.4
Previous Close
 1.67
Float %
49.1%
Change on Day
0.06
Shares Sold Short (mm)
-
Change % on Day
3.7%
Dividend Yield %
-
Day High/Low
 1.70/ 1.61
Diluted EPS Excl. Extra Items
0.20
52 wk High/Low
 1.70/ 0.93
P/Diluted EPS Before Extra
8.41x
Volume (mm)
0.0036
Avg 3M Dly Vlm (mm)
0.0078
Beta 5Y
1.05


 
Delayed Quote** | Last Updated on Oct-04-2023 12:00 AM (GMT-5)
TSXV:MPH - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Lariat Capital, Inc.
As of November 22, 1999, Lariat Capital, Inc. was acquired by Medicure, Inc. in a reverse merger transaction. Previously, Lariat Capital, Inc. operated as a junior capital pool company, which did not have significant operations. The company was incorporated in 1997.

United States and Canada
Biotechnology
-
0.00
0.00
Medicure International, Inc.
Medicure International, Inc. manufactures pharmaceutical products. The company was founded in 2000 and is headquartered in St James, Barbados. Medicure International, Inc. operates as a subsidiary of Medicure Inc.

Latin America and Caribbean
Pharmaceuticals
-
-
-
Medicure Pharma Inc.
Medicure Pharma Inc. distributes cardiovascular therapeutics products for cardiovascular market. The company was incorporated in 2005 and is based in Princeton, New Jersey. Medicure Pharma Inc. operates as a subsidiary of Medicure Inc.

United States and Canada
Health Care Distributors
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-29-2020
-
Buyback
Target
Medicure Inc. (TSXV:MPH)


0.30
Nov-13-2019
Dec-20-2019
Buyback
Target
Medicure Inc. (TSXV:MPH)


19.75
May-30-2019
-
Buyback
Target
Medicure Inc. (TSXV:MPH)


3.11
May-17-2018
-
Buyback
Target
Medicure Inc. (TSXV:MPH)


2.92
Oct-03-2017
Oct-03-2017
Merger/Acquisition
Seller
Apicore LLC

Medicure Inc. (TSXV:MPH)
110.51
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jul-31-2023
Earnings Calls
Medicure Inc., Q2 2023 Earnings Call, Jul 31, 2023
May-29-2023
Earnings Calls
Medicure Inc., Q1 2023 Earnings Call, May 29, 2023
May-26-2023
Annual General Meeting
Medicure Inc., Annual General Meeting, May 26, 2023
Apr-10-2023
Earnings Calls
Medicure Inc., Q4 2022 Earnings Call, Apr 10, 2023
Feb-01-2023
Executive/Board Changes - Other
Medicure Inc. Announces Resignation of Gerald McDole as Member of the Board of Directors

Competitors
Amylin Pharmaceuticals, LLC, Bristol-Myers Squibb Company (NYSE:BMY), Elan Pharmaceuticals, LLC, GSK plc (LSE:GSK), Iroko Pharmaceuticals, LLC, Janssen Biotech, Inc., Knoll Pharmaceutical Company, Merck & Co., Inc. (NYSE:MRK), Millennium Pharmaceuticals, Inc., Pentapharm Ltd., ReceptoPharm, Inc., Sandoz GmbH, Schering-Plough Corporation (Acquired), The Medicines Company


Advisors
Most Recent Auditor
Ernst & Young LLP
Private Placement Advisors
AG Edwards Inc., Bloom Burton & Co. Inc., Deutsche Bank Securities Inc., Leerink Partners LLC, Macquarie Private Wealth Inc., Merriman Capital, Inc., Montgomery & Co., LLC, Needham & Company, LLC, NOBLE Capital Markets, Inc., Paradigm Capital Inc., PI Financial Corp., RBC Capital Markets, LLC, Research Capital Corporation, RF Securities Clearing LP, Versant Partners Inc.
Public Offering Advisors
KPMG LLP (Canada), Lang Michener LLP
Key development Advisor
Beal Advisors LLC, Bloom Burton & Co. Inc.


Most Recent Auditor
Ernst & Young LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

03:21 AM
MPH
Medicure Inc 2023_10_05
Reports
15
ValuEngine, Inc.

Oct 02, 2023 06:25 AM
MPH
ValuEngine - Toronto Quantitative Stock Report for MPH
Reports
9
CFRA Equity Research

Oct 01, 2023 08:38 AM
MPH
Medicure Inc.
Reports
9
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Sep 21, 2023 06:00 PM
MPH
Rating Update for Medicure Inc
EPS Estimates*
3
MarketLine

Sep 20, 2023 06:01 AM
MPH
Medicure Inc
Reports
34
GlobalData

Sep 15, 2023 04:29 AM
MPH
Medicure Inc (MPH.CVE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
55
GlobalData

Sep 12, 2023 04:06 AM
MPH
Medicure Inc (MPH.CVE) - Financial Analysis Review
Reports
343
S&P Global Compustat

Sep 07, 2023 03:05 AM
MPH
Medicure Inc 2023_09_07
Reports
15
MarketLine

Aug 31, 2023 06:01 AM
MPH
Medicure Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
41
GlobalData

Aug 25, 2023 03:30 AM
MPH
Medicure Inc (MPH.CVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
38


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Friesen Ph.D., Albert David

2,475,595

23.72

4.0

Apr-27-2023


MM Asset Management Inc

2,410,567

23.10

3.9

Apr-10-2023


A.d. Friesen Enterprises Ltd

150,408

1.44

0.2

Apr-10-2023


Naimark F.R.C.P.(C), F.R.S.C, FC, L.L.D., M.D., O.C., O.M., Arnold 

84,194

0.81

0.1

May-09-2023


CentreStone Ventures Inc.

64,824

0.62

0.1

Apr-10-2023


Fawkes CA, MAcc, Brent 

57,376

0.55

0.1

May-09-2023


McDole B.Sc, M.B.A., MBA, Gerald P.

48,950

0.47

0.1

Dec-31-2022


Kinley C.A., CPA, James F.

47,100

0.45

0.1

Apr-10-2023


Quick, Peter C.

28,150

0.27

0.0

Apr-10-2023


Owens Ph.D., Neil 

6,400

0.06

0.0

Feb-01-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Naimark F.R.C.P.(C), F.R.S.C, FC, L.L.D., M.D., O.C., O.M., Arnold 
84,194
45,000
Fawkes CA, MAcc, Brent 
57,376
45,000
Friesen Ph.D., Albert David
2,475,595
16,000

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
AGGRASTAT (Future), Distribution of ReDS PRO Devices, Generic ANDA 2 (Future), Generic ANDA 3 (Future), PREXXARTAN, SNP, TARDOXAL/P5P (Future)


Upcoming Events
Date/Time
Type
Oct-27-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-05-2023
Aug-29-2023
Medicure Inc. (TSXV:MPH)
SEC
6-K
37 KB
Aug-29-2023
-
Medicure Inc. (TSXV:MPH)
SEDAR
News Releases
144 KB
Jul-28-2023
-
Medicure Inc. (TSXV:MPH)
SEDAR
News Releases
211 KB
Jul-28-2023
-
Medicure Inc. (TSXV:MPH)
SEDAR
Interim Financial Statements
322 KB
Jul-25-2023
-
Medicure Inc. (TSXV:MPH)
SEDAR
News Releases
139 KB
Jul-25-2023
Jul-24-2023
Medicure Inc. (TSXV:MPH)
SEC
6-K
29 KB
May-31-2023
May-26-2023
Medicure Inc. (TSXV:MPH)
SEC
6-K
119 KB
May-26-2023
-
Medicure Inc. (TSXV:MPH)
SEDAR
News Releases
203 KB
May-26-2023
Mar-31-2023
Medicure Inc. (TSXV:MPH)
SEDAR
Interim Financial Statements
317 KB
May-09-2023
-
Medicure Inc. (TSXV:MPH)
SEDAR
Management Proxy Materials
68 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Naimark F.R.C.P.(C), F.R.S.C, FC, L.L.D., M.D., O.C., O.M., Arnold  (Independent Director)
May-09-2023
Common Shares
45,000
13,837
Derivative Exercise and Retained Stock
114.81
Multiple
Fawkes CA, MAcc, Brent  (Independent Director)
May-09-2023
Common Shares
45,000
13,837
Derivative Exercise and Retained Stock
363.61
Multiple
Friesen Ph.D., Albert David (Founder, CEO & Chairman of the board)
Apr-21-2023 - Apr-27-2023
Common Shares
4,000
5,253
Open Market Acquisition
0.16
Multiple
-
Apr-21-2023
Common Shares
100
132
Open Market Acquisition
-
Exchange Announcement
-
Apr-27-2023
Common Shares
3,900
5,121
Open Market Acquisition
-
Exchange Announcement
Friesen Ph.D., Albert David (Founder, CEO & Chairman of the board)
Apr-20-2023
Common Shares
1,000
1,326
Open Market Acquisition
0.04
Multiple
Friesen Ph.D., Albert David (Founder, CEO & Chairman of the board)
Apr-14-2023
Common Shares
1,000
1,284
Open Market Acquisition
0.04
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Friesen, Albert David
Founder, CEO & Chairman of the board
888-435-2220
(204) 488-9823

Armstrong, Paul W.
Chairman of Scientific Advisory Board
204-487-7412
204-488-9823

Fawkes, Brent 
Independent Director
204-487-7412
204-488-9823

Naimark, Arnold 
Independent Director
204-487-7412
204-488-9823

Hanessian, Stephen 
Member of Scientific Advisory Board
204-487-7412
204-488-9823

Hassell, Trevor 
Member of Scientific Advisory Board
204-487-7412
204-488-9823

Karmazyn, Morris 
Member of Scientific Advisory Board
204-487-7412
204-488-9823

Kinley, James F.
Director
204-995-9594
204-488-9823
james@algernonpharmacuticals.com
Lincoff, A. Michael
Member of Scientific Advisory Board
204-487-7412
204-488-9823

Quick, Peter C.
Independent Director
(212) 747-1200
(212) 747-5651

Theroux, Pierre 
Member of Scientific Advisory Board
204-487-7412
204-488-9823

Weitz, Jeffrey 
Member of Scientific Advisory Board
204-487-7412
204-488-9823

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Friesen, Albert David
Founder, CEO & Chairman of the board
888-435-2220
(204) 488-9823

Owens, Neil 
President & COO
204-487-7412
204-488-9823

Uddin, Haaris 
Chief Financial Officer
(204) 478-5609
204-488-9823
huddin@waverleypharma.com
Saba, Reuben 
Vice President of Scientific & Medical Affairs
204-487-7412
204-488-9823

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
